Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma

Zhimin Zeng,Xiaoying Qian,Fanrong Liu,Yong Wang,Yong Yuan,Fang Chen,Xinwei Zhang,Shangkun Yuan,Renfang Chen,Bo Yu,Tong Wang,Yulong Yin,Yan Hui Li,Anwen Liu

DOI: https://doi.org/10.3389/fimmu.2023.1269596

IF: 7.3

2023-01-01

Frontiers in Immunology

Abstract:• please read through all the templates before choosing • pick the most relevant text template(s) from the following page and delete all others.• edit the text as necessary, ensuring that the original incorrect text is included for the record, please see the below. • please do not use any extra formatting when editing the templates, and only modify the red text unless absolutely necessary • submit to Frontiers following the instructions on this page.When the original text contained incorrect information, to preserve the scientific record, please include that text when editing the below templates. For example:There was a mistake in the Funding statement, an incorrect number was used. The correct number is "2015C03Bd051.". The publisher apologizes for this mistake.The original version of this article has been updated.In the published article, there was a mistake in the Funding statement. The funding statement for the Key Development Project of the Department of Science and Technology was displayed as "2015CBd051". The correct statement is "Key Development Project of Department of Science and Technology (2015C03Bd051).''